CKD-581 + lenalidomide + dexamethasone

CKD-581 + lenalidomide + dexamethasone is an investigational combination therapy for the treatment of multiple myeloma and potentially lymphoma that involves three drugs: CKD-581, lenalidomide, and dexamethasone. **CKD-581** is a novel, small molecule pan-histone deacetylase inhibitor (HDAC inhibitor) that induces cancer cell death by inhibiting HDAC class I and II enzymes, resulting in acetylation of histone H3 and tubulin, downregulation of the Wnt/β-catenin pathway, suppression of oncogenic proteins such as c-Myc and β-catenin, and induction of apoptosis via enhanced p53, p21, and caspase-3 activity[1][3][4]. **Lenalidomide** is an immunomodulatory drug that modulates cytokines, enhances T-cell and NK-cell responses, inhibits angiogenesis, and directly suppresses tumor cell growth[2]. **Dexamethasone** is a synthetic glucocorticoid used as an anti-inflammatory and immunosuppressive agent, and is a standard component of multiple myeloma therapy. This combination aims to integrate epigenetic modulation, immunomodulation, and corticosteroid anti-proliferative effects to potentiate anti-myeloma efficacy.

Other names

CKD-581 + lenalidomide + dexamethasone